Amgen Inc
Close on Nov 3, 2026Market cap $249.37BP/E 28.6Yield 2.09%
Amgen TEZSPIRE (tezepelumab-ekko by Year
TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%) (%)
Amgen TEZSPIRE (tezepelumab-ekko: 52.0% in FY2025, down 19.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| TEZSPIRE ® | 1,478 | — | 1,478 | 972 | 52%”
Source: Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Reported in Form 8-K Product Sales Detail by Product and Geographic Region.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | TEZSPIRE (tezepelumab-ekko — Severe Asthma) — Worldwide reported sales growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 52.0% | -19.0 pts | Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 71.0% | – | Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗ |
Cite this data
StockData. (2026). Amgen TEZSPIRE (tezepelumab-ekko (%), annual FY2024–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod-tezspire-yoy
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.
See a number that looks wrong?